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Abstract 
There are emerging reports that the family of a disintegrin and metalloproteinases 
(ADAM) are involved in the maintenance of the malignant phenotype of 
glioblastomas. Notably, ADAM proteases 10 and 17 might impair the immune 
recognition of glioma cells via the activating immunoreceptor NKG2D by cleavage of 
its ligands from the cell surface. Glioblastoma initiating cells with stem cell properties 
(GIC) have been identified as an attractive target for immunotherapy. However, GIC 
immunogenicity seems to be low. Here, we show that ADAM10 and ADAM17 are 
expressed on the cell surface of GIC and contribute to an immunosuppressive 
phenotype by cleavage of ULBP2. The cell surface expression of ULBP2 is 
enhanced upon blocking ADAM10 and ADAM17 and treatment with ADAM10 and 
ADAM17 specific inhibitors leads to enhanced immune recognition of GIC by natural 
killer cells. Therefore, ADAM10 and ADAM17 constitute suitable targets to boost an 
immune response against GIC. 
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Introduction 
The treatment of glioblastoma remains a major challenge in the field of 
neurooncology. The current standard of care includes surgery, radiotherapy and 
alkylating chemotherapy. The median survival times with this treatment are less than 
12 months according to a population-based study 1. One promising approach to 
enhance the survival of glioblastoma patients is immunotherapy 2,3. Glioma cells are 
per se prone to an attack by natural killer (NK) cells due to expression of ligands for 
activating immunoreceptors like NKG2D 4. NKG2D is a C-type lectin-like 
homodimeric receptor expressed by NK, γδ T and CD8+ αβ T cells. The ligands for 
NKG2D include the MHC class I chain-related proteins A and B (MICA/B) and UL16-
binding proteins (ULBP1–6) which are not expressed by most normal tissues, but up-
regulated upon malignant transformation, infection or cellular stress 5,6. MICA, MICB 
and ULBP1-3 are expressed on the cell surface of human glioma cells 7,8. In a 
mouse model of glioma, the growth of syngeneic intracerebral tumors was inhibited 
by peripheral vaccination with MICA-overexpressing irradiated tumor cells and 
vaccination resulted in NK and T cell activation in vivo indicating a possible 
therapeutic use of the NKG2D receptor-ligand system in glioblastoma 7. However, 
the immunosuppressive micromilieu within glioblastomas impairs the NKG2D system 
via downregulation of cell surface expression of MICA and ULBP2 mediated by 
transforming growth factor (TGF)-β and cleavage by metalloproteinases 8.  
Among these metalloproteinases, members of the a disintegrin and 
metalloproteinase (ADAM) family confer malignancy in several types of cancer, e.g. 
breast cancer or malignant gliomas 9. ADAMs are involved in the activation of 
preforms of cytokines and growth factors or shed the extracellular domains of cell 
surface proteins 9. In the human glioma cell line U87, ADAM17, also known as tumor 
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necrosis factor alpha converting enzyme (TACE), contributes to the malignant 
phenotype of these cells including promotion of cell growth, viability, invasiveness 
and neo-angiogenesis in vitro and tumor growth in vivo which is in part mediated by 
epidermal growth factor receptor - phosphoinositide 3-kinase/AKT signaling 10. 
ADAM10 promotes glioma cell migration by cleavage of the adhesion molecule N-
cadherin from the cell surface in a protein kinase C-dependent manner 11. Moreover, 
ADAM10 and ADAM17 might even be involved in the maintenance of the stem cell 
phenotype of GIC 12. Notably, ADAM10 and ADAM17 cleave MICA and ULBP2 from 
the cell surface of B cell line C1R, the embryonic fibroblast cell line 293T and 
cervical, mammary, prostate and pancreatic carcinoma cell lines 13,14. However, to 
date little is known about a possible role of ADAM10 and ADAM17 in the regulation 
of cell surface expression of NKG2D ligands (NKG2DL) and thus a possible 
modulation of immunogenicity in glioma cells. 
A crucial issue for an effective immunotherapy is the choice of the target. In recent 
years, there is growing evidence for the presence of glioma-initiating cells within 
glioblastomas owing stem cell properties 15. We here refer to these cells as glioma 
initiating cells (GIC) in the following. In a hierarchical tumor model, GIC are crucial 
for the initiation and maintenance of glioblastomas and therefore constitute an 
attractive therapeutic target. GIC are defined by the stem cell properties self-
renewal, multipotency and tumorigenicity, forming tumors resembling the initial 
human tumors 16,17. Current treatments might spare enough GIC to allow regrowth of 
the tumors. Despite the expression of ligands on GIC for activating immunoreceptors 
like NKG2D or NKp46 18,19, several immunosuppressive mechanisms of GIC have 
been described which might lead to immune evasion. This includes the induction of 
regulatory T cells or the inhibition of proliferation and the apoptosis of T cells in vitro, 
5 
in part mediated by signal transducer and activator of transcription 3 (STAT3) 20,21. A 
defective antigen processing machinery in GIC enhances their ability to evade a T 
cell-mediated immune response 19. We have previously defined a contribution of the 
atypical human leukocyte antigen (HLA)-E to this immunosuppressive phenotype of 
GIC towards innate immunity 22. 
In the present work, we describe the modulation of immunogenicity of GIC by 
membrane-bound ADAM10 and ADAM17. Blocking of ADAM10 and ADAM17 with 
specific inhibitors or the use of small interfering RNA (siRNA) decreases cleavage 
from the cell surface and therefore, as a direct consequence the cell surface 
expression of ULBP2 is enhanced. Treatment with ADAM10 and ADAM17 specific 
inhibitors leads to enhanced immune recognition of GIC in cytotoxicity assays and to 
enhanced release of interferon (IFN)-γ by NK cells in co-culture with these GIC. 
Therefore, ADAM10 and ADAM17 constitute suitable targets to boost an immune 
response against GIC. 
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Materials and methods 
 
Materials and cell lines 
The human malignant glioma cell line LN-229 was originally provided by Dr N. de 
Tribolet (Lausanne, Switzerland) and renamed LNT-229 for clarification (T for 
Tübingen). The cells were maintained in DMEM supplemented with 2 mM L 
glutamine and 10% fetal calf serum (FCS) (all Invitrogen, Basel, Switzerland). The 
GIC lines GS-2, GS-5, GS-7 and GS-9 have been characterized for stemness 
properties earlier 23. In summary, the cell lines expressed the stemness markers 
Sox2 and nestin as undifferentiated cultures and either neuronal (MAP2, 
neurofilament), oligodendroglial (galactocerebroside C) or glial markers (glial fibrillary 
acidic protein) upon differentiation. Moreover, the GIC lines were characterized by 
self-renewal and their tumorigenicity was confirmed in vivo. All GIC lines were 
cultured in 75 cm2 culture flasks and maintained in neurobasal medium with B-27 
supplement (20 µl/ml) and glutamax (10 µl/ml) from (all Invitrogen) fibroblast growth 
factor (FGF)-2, epidermal growth factor (EGF) (20 ng/ml each; Peprotech, Rocky 
Hill, PA) and heparin (32 IE/ml; Ratiopharm, Ulm, Germany). Stem cell factors were 
supplemented twice a week, complete medium changed once a week. Cells were 
passaged when spheres reached an estimated diameter of 500 μm or an estimated 
density of 5 x 104 cells/cm2. Spheres were dissociated mechanically and 
enzymatically. Briefly, we spun down the cells and resuspended the pellet in 1 ml 
accutase (PAA, Wien, Austria). After mechanical dissection by pipetting up and 
down, we incubated the cells at 37°C for 5 minutes. From previous work we know 
that accutase does not alter the expression level of NKG2DL on the cell surface of 
glioma cells 4,8. The NK cell line NKL 24 was cultured in RPMI 1640 medium (PAA) 
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containing 15% fetal calf serum (FCS), 2 mM L-glutamine (Gibco Life Technologies, 
Paisley, UK), penicillin (100 IU/ml)/streptomycin (100 mg/ml) (Gibco), 1 mM sodium 
pyruvate and 100 U/ml interleukin 2 (Peprotech). Specific inhibitors for ADAM10 
(GI254023X) and ADAM10 and 17 (GW280264X) were from Glaxo Smith Kline 
(London, UK). GI254023X is considered being 100 fold more specific in blocking 
ADAM10 than ADAM17 25. SD-208 26, a transforming growth factor (TGF)-β receptor 
I kinase inhibitor specially targeting activin receptor-like kinase 5, was purchased 
from Tocris Bioscience (Bristol, UK).  
 
Monoclonal antibodies and flow cytometry 
Cell surface expression was assessed with the following monoclonal antibodies 
(mAbs): ADAM10 (Clone 163003, APC-conjugated; mouse IgG2b; R&D Systems, 
Minneapolis, MA) and ADAM17 (Clone 111633, Fluorescein-conjugated; mouse 
IgG1; R&D Systems) and hybridoma supernatants: MICA (clone AMO1, 
unconjugated, mouse IgG1), MICB (clone BMO1, unconjugated, mouse IgG1), 
ULBP1-3 (clones AUMO1; BUMO1 and CUMO3, all unconjugated, mouse IgG1 27). 
Isotype matched antibodies unconjugated IgG1 (clone MOPC 21; Sigma-Aldrich, 
Buchs, Switzerland), FITC-conjugated IgG1 (clone MOPC 21; Sigma-Aldrich) and 
APC-conjugated IgG2b (clone MPC-11; Biolegend, San Diego, CA) were used as 
controls. The PE-conjugated goat anti-mouse IgG (Dako, Freiburg, Germany, dilution 
1:20) was used as secondary antibody where appropriate. The cells were 
dissociated as described, preincubated in PBS with 2% FCS and stained with 
specific mAb or matched mouse Ig isotype for 30 min on ice, followed by incubation 
with the PE-conjugated secondary antibody for 30 min where appropriate. Then the 
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cells were washed with PBS containing 2% FCS. Flow cytometry was performed with 
a CyAn ADP Analyzer (Beckman Coulter, Nyon, Switzerland). Specific fluorescence 
index (SFI) was calculated by dividing median fluorescence obtained with the 
specific antibody by median fluorescence obtained with the control antibody.  
 
Viability and proliferation 
2.5 x 105 GIC were seeded in a 24 well plate in the presence of increasing 
concentrations of GI254023X, GW280264X ( both 3 µM) or DMSO for 48 h. Viability 
and cell concentration were assessed by Trypan blue staining using Vi-CELL™ XR 
(Beckman Coulter, Nyon, Switzerland). The cell count was calculated based on the 
cell concentration and the predetermined cell culture volume.  
 
Limiting dilution sphere formation assay 
For the sphere formation assays, GS-5 cells were mechanically and enzymatically 
dissociated to a single cell suspension with accutase, diluted and seeded in 
triplicates at 10, 100, 1000 and 10.000 cells/well in a 96 well plate under stem cell 
culture conditions. After 24 h, 50 μl stem cell medium containing GI254023X, 
GW280264X (both to a final concentration of 3 μM) or DMSO were added. After 7 
days, another 100 μl of stem cell medium containing inhibitors (final concentration 3 
μM) or DMSO was supplemented. The number of spheres was counted in each well 
after 14 days. 
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Immunocytochemistry 
For undifferentiated GIC, cytospin samples were prepared. For differentiation, GIC 
were dissociated and dissolved in neurobasal A medium containing B-27 supplement 
(20 µl/ml), FCS (10%), and glutamax (10 µl/ml) (all Invitrogen) as well as cyclic 
adenosine monophosphate (cAMP) (0.75 mM) and retinoic acid (1 mM) (both Sigma-
Aldrich)23. GIC were seeded on glass coverslips in a 24 well plate (both TPP, 
Trasadingen, Switzerland) for 8 days. Cytospin samples and coverslips were either 
fixed in methanol for glial fibrillary acidic protein (GFAP) or 4% paraformaldehyde for 
nestin, ß-3-tubulin and galactocerebroside C (GalC), treated with H2O2 and blocked 
with PBS containing 10% swine serum and 0.3% Triton X. The following antibodies 
were used for primary stem cell staining: nestin (clone 10C2, IgG1; Zytomed, Berlin, 
Germany; diluted 1:100), GFAP (ab Z0334, polyclonal rabbit IgG; Dako; diluted 
1:1000), ß-3-tubulin (ab18207, polyclonal rabbit IgG; Abcam, Cambridge MA; diluted 
1:1000) and GalC (MAB342, mouse IgG3, Millipore, Billerica, MA; diluted 1:200). As 
isotype controls, we used mouse IgG1 (Dianova, Hamburg, Germany), mouse IgG3 
(eBioscience, Vienna, Austria) or polyclonal rabbit IgG (Vector Laboratories, 
Burligame, CA). The cells were incubated at 4°C overnight. Goat anti-mouse IgG 
Alexa Fluor 594-coupled secondary antibody (Invitrogen, A11032) or goat anti-rabbit 
IgG Alexa Fluor 594-coupled secondary antibody (Invitrogen, A11034) were used at 
1:100. 4',6-Diamidino-2-Phenylindole (DAPI) for nuclear counterstain was from 
Invitrogen (D3571) and used at 1:2000. Slides were mounted using fluorescence 
mounting medium (Dako; S3023). Images were aquired by using an Axioplan II 
fluorescence microscope (Carl Zeiss AG, Feldbach, Germany). 
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Real-Time PCR 
RNA was prepared from the cell lines using NucleoSpin RNA II Kit (Macherey-Nagel, 
Düren, Germany). Subsequently, cDNA was generated using SuperScript II Reverse 
Transcriptase (Invitrogen). RNA and DNA concentrations were determined using 
NanoDrop (Thermo Scientific, Waltham, MA). 
cDNA amplification was monitored using SYBRGreen chemistry on the ABI 
PRISM7000 Sequence Detection System (Applied Bio-Systems, Weiterstadt, 
Germany) using the following specific primers (forward/reverse): GAPDH: described 
in 22. ADAM10: 5’-GGATGGAAAAGGAACCCAAT-3, 5’-
ACGAAGAACAGGGAACATGG-3’; ADAM17 5’-TTGAGCGATTTTGGGATTTC-3’, 
5’-AAACCAGAACAGACCCAACG-3’. Primers for MICA, MICB and ULBP1-3 have 
been published 28. Data analysis was done using the DDCT method for relative 
quantification. Briefly, threshold cycles (CT) for GAPDH RNA (reference) and 
specific primers (sample) were determined in duplicate. The expression levels were 
determined following the formula: rI=2-[CTTarget - CT GAPDH] and then referred to whole 
normal brain cDNA obtained by Lonza (Walkersville, MD). 
 
RNA interference 
To silence ADAM10 and ADAM17 expression, the glioma cells were transfected with 
ADAM10 and ADAM17 ON-TARGETplus SMART Pool siRNA (Dharmacon, 
Lafayette, CO) or non-targeting SMART pool siRNA (Dharmacon) as a control 
respectively. Glioma cells were seeded in 6 well plates overnight and subsequently 
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transfected with siRNA using lipofectamine RNAi (Invitrogen). Gene silencing was 
verified by real-time PCR and by flow cytometry 72 h after transfection.  
 
Enzyme-linked immunosorbent assay (ELISA) 
For the detection of soluble ULBP2 (sULBP2) in cell culture supernatants, 5 x 105 
cells were cultured in 500 μl B-27 supplement free-medium and treated as indicated. 
The supernatants were collected after 48 h and then analyzed by sandwich ELISA 
for sULBP2 using the Duoset ELISA Kit (Duoset DY1298; R&D Systems, 
Minneapolis, MA).  
To assess IFN-γ secretion by NKL, 2 x 104 GIC were pretreated with either GW or 
DMSO as a control for 24 h and subsequently co-cultured with 4 x 105 NK cells in 
500 μl serum free RPMI medium for 12 h. The conditioned media from this co-culture 
were collected and analyzed using the IFN-γ ELISA MAX standard kit obtained from 
Biologend (Uithoorn, Netherlands). 
 
Cytotoxicity assay 
We used a flow cytometry-based cytotoxicity assay 29 which employs the membrane 
dye PKH-26 and the viability dye ToPro3 as described 22. Briefly, the target cells 
were incubated with PKH-26 dissolved in Diluent C (1:250; all from Sigma–Aldrich) 
for 3 min. Staining was stopped by washing with RPMI 1640 medium containing 10% 
FCS. Then the effector and target cells were coincubated at varying effector to target 
(E:T) ratios for 3 h. ToPro3 (Invitrogen) was added to the vials prior to measurement 
and incubated for 30 seconds. The percentage of target cell lysis was determined by 
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flow cytometry using the CyAn ADP Analyzer (Beckman Coulter). Background 
elimination was done by subtraction of spontaneous lysis of target cells only. All 
experiments were done in duplicates. 
 
Statistical analysis 
The experiments were performed 2 to 3 times as indicated. Statistical significance 
was calculated by student`s two-tailed t-test (* p<0.05; ** p<0.01) or by ANOVA, 
using GraphPad Prism software, version 5.0 (La Jolla, California) where indicated. 
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Results 
GIC lines express NKG2DL 
The expression of NKG2D ligands in the glioma cell line LNT-229 and in GIC lines 
GS-2, GS-5, GS-7 and GS-9 was assessed by real-time PCR and flow cytometry 
(Figure 1). All investigated cell lines variably express NKG2DL on the cell surface, 
predominantly MICA and ULBP2 (Figure 1B, C). This was only roughly paralleled by 
the expression on mRNA level (Figure 1A), indicating additional mechanisms of 
posttranscriptional and/or –translational regulation as they are well described for 
regulation of NKG2DL cell surface expression 30. 
 
GIC lines express ADAM10 and ADAM17 on the cell surface 
The expression of ADAM10 and ADAM17 in GIC was assessed by real-time PCR 
and flow cytometry (Figure 2). ADAM10 and ADAM17 genes are transcribed in all of 
the investigated GIC lines with expression levels being higher in GS-5, GS-7 and 
GS-9 compared to GS-2 (Figure 2A). In parallel, ADAM10 and, to a lesser extent, 
also ADAM17 protein can also be detected on the cell surface of GIC (Figure 2B, C). 
In line with the relative low mRNA expression levels of ADAM10 and ADAM17 in GS-
2, cell surface protein expression for ADAM10 was lower than in the other GS lines 
and only marginal for ADAM17 (Figure 2B, C). While exhibiting strong expression of 
ADAM10, the cell surface level of ADAM17 in GS-9 was low (Figure 2B, C). GS-7 
showed the strongest cell surface expression level of ADAM17 of the GIC lines 
tested here and in addition also high levels of ADAM10.  
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The inhibition of ADAM10 and ADAM17 leads to an upregulation of ULBP2 cell 
surface expression on GIC  
We next assessed the role of ADAM10 and ADAM17 in the regulation of NKG2DL 
expression. GS-2, GS-5, GS-7 and GS-9 cells were treated with specific inhibitors 
GI254023X (for ADAM10) and GW280264X (for ADAM10 and ADAM17). The level 
of NKG2DL was assessed by flow cytometry. We found a significant upregulation of 
ULBP2 in all investigated cell lines (Figure 3A) in a time- and concentration-
dependent manner (shown exemplarily for GS-7, Figure 3B). While the expression 
levels of MICB, ULBP1 and ULBP3 were unaltered, we observed a trend towards 
upregulation of MICA in GS-5 (Figure 3A). Next, we assessed the presence of 
sULBP2 in conditioned cell culture supernatants of LNT-229 and GIC cultures by 
ELISA. sULBP2 concentrations in the supernatants decreased significantly following 
treatment with GI254023X and were below the detection limit upon treatment with 
GW280264X, while the level of ULBP2 on the mRNA level remained largely 
unaltered as assessed by real-time PCR (Figure 3C, D). In order to confirm the 
specificity of the effects mediated by the inhibitors, we used small interfering RNA to 
transiently silence ADAM10 and ADAM17 gene expression in GS-7. We achieved an 
efficacy of gene silencing of more than 90% as assessed by real-time PCR (Figure 
4A). The knock-down of ADAM10 and ADAM17 cell surface expression was verified 
by flow cytometry (Figure 4B). The knock-down of either ADAM10 or ADAM17 gene 
expression as well as the combined knock-down led to a significant upregulation of 
ULBP2 on the cell surface while the expression of the other NKG2DL was largely 
unaffected (Figure 4D, E) similar to the effect mediated by the inhibitors  
We assessed the proliferation and survival of GIC upon treatment with the ADAM 
inhibitors or knock-down of ADAM expression. The viability of GIC was not altered 
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following treatment with the inhibitors or upon knock-down. This is shown 
exemplarily for the inhibitors in GS-7 (Suppl. Figure 1A). The proliferation of GS-7 
cells was significantly reduced upon treatment with GW280264X or ADAM10/17 co-
knockdown (Suppl. Figure 1B and data not shown) respectively, consistent with 
previous data12.  
 
Blocking of TGF-β signaling does not alter upregulation of ULBP2 cell surface 
levels mediated by inhibition of ADAM10 and ADAM17 
In order to investigate a possible involvement of endogenous TGF-β in the ADAM10 
and ADAM17-mediated effects on ULBP2 cell surface expression we used SD-208, 
a TGF-beta receptor I kinase inhibitor, which efficiently blocks TGF-β signaling in 
glioma cells 26. GS-7 cells were treated with SD-208 for 48 h and blockade of 
SMAD2 phosphorylation was verified by immunoblot (data not shown). The 
expression of ADAM10 and ADAM17 remained unaltered as assessed by flow 
cytometry (Figure 5A). We observed a tendency to enhanced expression of MICA 
and ULBP2, though statistically not significant (Figure 5B). Next, the cells were 
treated with GW280264X for 24 h and no further increase in MICA expression was 
observed. However, expression of ULBP2 in SD-208 treated cells was markedly 
increased  (Figure  5B),  suggesting  that  cleavage  of  ULBP2  by  ADAM10  and  ADAM17  is  largely 
independent of TGF‐β.  
 
The inhibition of ADAM10 and ADAM17 enhances immunogenicity of GIC  
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To define a role for ADAM10 and ADAM17 in modulating the immunogenicity of GIC, 
we used either GI254023X or GW280264X pretreated GS-7 or GS-9 cells as targets 
in a cytotoxicity assay with NKL cells as effectors. We observed a significantly 
increased susceptibility towards NK cell mediated lysis following treatment with the 
ADAM10 and ADAM17 specific inhibitor GW280264X and to a lesser extent by the 
ADAM10 specific inhibitor GI254023X in GS-7 (Figure 6A). In GS-9, treatment with 
ADAM inhibitors led to enhanced susceptibility towards NK cells, however the effect 
of GW280264X was not superior to GI254023X (Figure 6B). The relative increase of 
ULBP2 expression following treatment with GW280264X compared to GI254023X 
was highly significant in GS-7 cells (p=0.008) and present to a lesser degree in GS-9 
(p=0.02) (Figure 3A). Thus, the slight additional upregulation of ULBP2 levels in GS-
9 by GW280264X compared to GI254023X might not be sufficient to be translated in 
an enhanced immune recognition by NKL cells. Since the secretion of IFN-γ by 
activated NK cells is considered an important link between the innate and adaptive 
immune response, we analyzed the conditioned media of NKL and GS-7 co-cultures 
for the level of IFN-γ by ELISA. NKL cells were co-cultured with GS-7 cells pre-
treated or not with GW280264X (3 μM for 48 h). The levels of IFN-γ in the 
supernatant of co-cultures with GS-7 cells pre-treated with GW280264X were 
significantly increased (Figure 6C).  
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Discussion 
In this study, we define a role of ADAM10 and ADAM17 for the modulation of 
immunogenicity of GIC by influencing the NKG2D receptor-ligand system. The 
NKG2DL MICA, MICB and ULBP1-3 are expressed on the cell surface of GIC lines. 
The expression of NKG2DL in gliomas, especially of MICA and ULBP2, is known to 
be influenced by various factors, including downregulation by TGF-β and cleavage 
by metalloproteinases 8. ADAM10 and ADAM17 belong to a family of proteases 
involved in the shedding of extracellular domains of cell surface proteins 9. Both 
proteins cleave NKG2DL, namely MICA and ULBP2 as demonstrated in malignant 
and non-malignant cell lines 14,31. A single report provides evidence that ADAM17 is 
crucially involved in the shedding of soluble MICB from the cell surface of U373 
transfectants overexpressing MICB within detergent-resistant membrane 
microdomains (DRM) 32. In this work, we investigated the role of ADAM10 and 
ADAM17 in modulating the cell surface expression of NKG2DL in GIC. These GIC 
lines have been described before for their stemness properties 23. We adhered to the 
stem cell permissive culture conditions to assure maintenance of the stem cell 
phenotype and verified self-renewal capacity and multipotency of GIC. ADAM10 is 
expressed on all GIC lines investigated here. The strongest ADAM17 expression 
was present in GS-7. Interference with ADAM10 and ADAM17 function by specific 
pharmacological inibitors or gene silencing with siRNA led to a strong upregulation of 
ULBP2 expression on the cell surface. sULBP2 concentrations in the supernatants 
decreased significantly following treatment with the inhibitors, while the level of 
ULBP2 on the mRNA level remained unaltered, underscoring the view that ADAM10 
and ADAM17 decrease ULBP2 cell surface expression via proteolytic cleavage.  
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Few reports indicate a link between effects mediated by ADAM proteases and TGF-
β. TGF-β-mediated effects on glioma cell motility and invasiveness could be 
abrogated in part by blocking ADAM17 33 and ADAM12 expression was upregulated 
by TGF-β in mammary carcinoma cells 34. The cleavage of ULBP2 from the cell 
surface by ADAM10 and ADAM17, however, seems to be largely independent from 
TGF-β. Previously, the abrogation of TGF-β signaling led to an upregulation of MICA 
and ULBP2 on non-GIC 8. We observed a tendency to enhanced expression of 
MICA and ULBP2 on the cell surface of GS-7 cells treated with SD-208, though 
statistically not significant. These cells were subsequently treated with GW280264X 
for 24 h and no further increase in MICA expression was observed. However, the 
levels of ULBP2 in these cells with blocked TGF-β signaling were markedly 
increased, showing that increased ULBP2 levels upon inhibition of ADAM10 and 
ADAM17 are largely independent from TGF-β, but rather due to a direct blockade of 
ADAM-mediated ULBP2 cleavage. 
In contrast to previous observations in HeLa cervix carcinoma cells 14, we found a 
minor upregulation of MICA only in GS-5 following impairment of ADAM10 and 
ADAM17. The sheddase activity of ADAM10 and ADAM17 is not dependent on a 
specific sequence motif but rather on the length of the stalk region of the NKG2DL 14. 
Notably, the most common MICA variant MICA08 is not cleaved by ADAM 
proteases, but released in endosomes 35. This might explain variations in NKG2DL 
cleavage observed in different cell lines of different tissue origin 14 32 and our 
findings. Moreover, shedding of MICA seems to depend critically on its association to 
endoplasmic reticulum protein 5 (ERp5) 36. An impairment of this association in our 
GIC lines might be involved in the lack of shedding of MICA, a possible mechanism 
which warrants further investigation. The inhibitors used here are highly specific for 
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ADAM10 (GI254023X) or ADAM10 and ADAM17 (GW280264X) respectively. The 
specificity of GI254023X and GW280264X has been repeatedly confirmed and these 
inhibitors have been used in various subsequent investigations 12-14,25,37. Moreover, 
we used RNA interference to silence ADAM10 and ADAM17 expression in a 
sequence-specific manner using appropriate controls and obtained the same results 
as with the pharmacological inhibitors. 
Collectively, our data provide strong evidence that, in accord with the present 
literature, ULBP2 expression on GIC is substantially reduced through cleavage by 
ADAM10 and ADAM17. We do not assume that the cleavage of NKG2DL is a 
specific mechanism in GIC since the sheddase activity of ADAM10 and ADAM17 
depends on the length of the stalk region of the NKG2DL as described above. 
However, it is of greater importance that, when targeting ADAM proteases to 
enhance immune response against glioma cells, the GIC are not spared. 
To date, little is known about the role of ADAM proteases in regulating immune 
function in glioma. We show here, that inhibition of ADAM10 and ADAM17 leads to 
enhanced lysis of GIC by NK cells. Moreover, we found significantly increased levels 
of IFN-γ in the supernatant of co-cultures of NK cells with GIC pre-treated with an 
ADAM inhibitor. This is in line with the results from a recent report investigating other 
tumor entities than glioma 13. Since IFN-γ is a main regulator of T-cell activity, 
inhibition of ADAM10 and ADAM17 and subsequent upregulation of ULBP2 might 
therefore also enhance adaptive immune responses through induction of IFN-γ 
secretion by NK cells.  
As outlined earlier, ADAM10 and ADAM17 are furthermore involved in the 
maintainance of the malignant phenotype of glioma cells regarding migration, 
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invasion, neo-angiogenesis or proliferation 10,11. Recently, a role for ADAM10 and 
ADAM17 for the maintainance of sphere formation and self-renewal of sphere 
forming cells derived from human gliomas kept under stem cell culture conditions 
was proposed 12. Here we focused on the modulation of the immunophenotype of 
GIC by ADAM proteases rather than the stem cell phenotype. Nevertheless, we 
reproduced the finding of reduced proliferation and decreased number of spheres in 
a limiting dilution assay upon inhibition of ADAM10 and ADAM17 (Suppl. Figure 3) 
as previously reported 12. 
In summary, we demonstrate that ADAM10 and ADAM17 are involved in the 
modulation of immunogenicity of glioblastoma stem-like cells. ADAM10 and ADAM17 
cleave ULBP2 from the cell surface and therefore warrant further investigation as 
possible targets to boost an immune response towards these cells. 
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Figure legends 
Fig. 1: GIC lines express NKG2D ligands. The expression of NKG2DL in GIC was 
assessed on the transcriptional and on the cell membrane level. (A) MICA, MICB 
and ULBP1-3 mRNA expression was analyzed by real-time PCR. Data are 
expressed relative to normal brain cDNA and represent mean relative expression ± 
SD from 3 independent experiments. (B, C) GIC were stained with mAbs for MICA 
(clone AMO1), MICB (clone BMO1), ULBP1 (clone AUMO1), ULBP2 (clone 
BUMO1), ULBP3 (clone CUMO3) or isotype-matched Ig, followed by staining with a 
PE-labelled anti-mouse secondary antibody. Flow cytometry was performed and 
data in (B) represent mean SFI values ± SD from 3 independent experiments (SFI=1 
is marked with dotted line); ** p<0.01, * p<0.05; student`s two tailed t-test). In (C), 
representative histograms from flow cytometry including the respective SFI values 
are shown (curve in light grey: isotype control, dark grey: specific MICA,B or ULBP1-
3 mAb). 
 
Fig. 2: GIC lines express ADAM10 and ADAM17 on the cell surface. (A) 
ADAM10 and ADAM17 mRNA expression was determined by real-time PCR. Data 
are expressed relative to the expression of normal brain cDNA and represent mean 
relative expression ± SD from 3 independent experiments. (B) GIC were stained with 
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directly labelled mAbs for either ADAM10 (Clone 163003), ADAM17 (Clone 111633) 
or isotype-matched Ig. Data represent mean SFI values ± SD from 3 independent 
experiments (SFI=1 is marked with dotted line). In (C), representative histograms 
from flow cytometry including the respective SFI values are shown (curve in light 
grey: isotype control, dark grey: specific ADAM10 or ADAM17 mAb). 
 
Fig. 3: Inhibition of ADAM10 and ADAM17 using specific inhibitors leads to an 
upregulation of ULBP2 cell surface levels and to decrease of sULBP2 in cell 
culture supernatants. (A) The GIC lines GS-2, GS-5, GS-7 and GS-9 were 
incubated with GI254023X (for ADAM10) or GW280264X (for ADAM10 and 
ADAM17) respectively (3 µM; 48 h). The cells were subsequently stained with mAbs 
for MICA, MICB, ULBP1-3 or isotype-matched Ig, followed by staining with a PE-
labelled anti-mouse secondary antibody. Flow cytometry data represent mean SFI ± 
SD from 3 independent experiments (SFI=1 is marked with a dotted line; ** p<0.01, * 
p<0.05; student`s two tailed t-test). (B) GS-7 cells were treated with increasing 
concentrations of GI254023X or GW280264X for various time points. The cells were 
subsequently stained with mAb for ULBP2 or isotype-matched Ig, followed by 
staining with a PE-labelled anti-mouse secondary antibody. Flow cytometry data 
represent mean SFI ± SD from 3 independent experiments. (C) GS-7 cells were 
treated with GW280264X (3 µM; 48 h). ULBP2 mRNA expression was determined by 
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real-time PCR. Data are expressed relative to the expression of normal brain cDNA 
and represent mean relative expression ± SD from 3 independent experiments. (D) 
GIC or LNT-229 cells were treated with DMSO, GI254023X (3 µM) or GW280264X 
(3 µM) for 48 h, then cell culture supernatants were harvested. The levels of sULBP2 
were assessed by ELISA. Data represent mean concentrations ± SD from 2 
independent experiments. 
 
Fig. 4: ADAM10 and ADAM17 gene silencing leads to an upregulation of 
ULBP2 cell surface expression. The GIC line GS-7 was transfected with control 
(siCtrl) or siRNA targeting ADAM10 (siADAM10) or ADAM17 (siADAM17). (A,B) The 
cells were harvested 72 h later and knock-down efficiency was confirmed by real-
time PCR (A). Data are expressed as percentage of ADAM10 and 17 expression in 
cells following ADAM10/ADAM17 gene silencing relative to control siRNA and 
represent mean relative expression ± SD from 3 independent experiments. (B) The 
knock-down efficiency was further confirmed by flow cytometry with ADAM10 or 
ADAM17 specific mAB (curve in light grey: isotype control, dark grey: specific 
ADAM10 or ADAM17 mAb).  (C, D) GS-7 cells transfected with either siADAM10, 
siADAM17 or both were stained with mAbs for MICA, MICB, ULBP1-3 or isotype-
matched Ig, followed by staining with a PE-labelled anti-mouse secondary antibody. 
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Flow cytometry data represent mean SFI values ± SD from 3 independent 
experiments (** p<0.01, * p<0.05; student`s two tailed t-test). 
 
Fig. 5: Blocking of TGF-β signaling does not alter upregulation of ULBP2 cell 
surface levels mediated by inhibition of ADAM10 and ADAM17. (A) GS-7 cells 
were treated with SD-208 (2 μM) or DMSO for 48 h. The levels of ADAM10 and 
ADAM17 at the cell surface were assessed by flow cytometry. In (B) the cells were 
treated as in (A) followed by treatment with either GW280264X (3 µM, 24 h) or 
DMSO. The levels of MICA, MICB and ULBP1-3 were assessed by flow cytometry. 
Flow cytometry data represent mean SFI values ± SD from 3 independent 
experiments. 
 
Fig. 6: The inhibition of ADAM10 and ADAM17 enhances immunogenicity of 
GIC. (A) GS-7 and (B) GS-9 cells were incubated with GI254023X or GW280264X (3 
µM; 48 h) and then used as targets in a cytotoxicity assay with NKL cells as 
effectors. Target cells were stained with the membrane dye PKH-26 and then co-
cultured with NKL cells at various effector to target (E:T) ratios for 3 h in duplicates. 
The cells were stained with the viability marker ToPro3 to identify the lysed cells by 
flow cytometry. Specific lysis was calculated by substraction of background lysis 
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from the fraction of dead cells (n=2). Statistics were done by ANOVA (** p=0.01*, 
p=0.05  for GI254023X pretreated, + p=0.05 for  GW280264X pretreated cells.) (C) 
GS-7 cells were pretreated with either GW280264X (3 µM, 48 h) or DMSO, and then 
co-cultured with NKL cells (12 h, effector to target ratio 20:1). Conditioned media 
were collected from co-cultures or NKL cells alone and concentration of IFN-γ was 
assessed by ELISA. Results represent mean concentrations ± SD of two 
independent experiments. 
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Supplementary materials 
Supplementary Figure 1: Proliferation of GSC is inhibited through inhibition of 
ADAM10 and ADAM17.  2.5 x 105 GS-7 cells were seeded in a 24 well plate in the 
presence of increasing concentrations of GI254023X or GW280264X (3 µM) or of 
DMSO for 48 h. Viability (A) and the cell count (B) were assessed by Trypan blue 
staining using Vi-CELL™ XR. Viability (%) and cell count data represent mean 
values ± SD from 3 independent experiments (* p<0.05; student`s two tailed t-test). 
 
Supplementary Figure 2: Multipotency of GSC. (A) Cytospin samples of GS-9 
GSC under stem cell culture conditions (left column) or after 8 days under 
differentiating culture conditions (right column) were prepared and stained for nestin, 
β-3 tubulin, GalC or GFAP (green), counterstaining of cell nuclei was performed with 
DAPI (blue). Note the scale bar in the upper left image (50 µm). 
 
Supplementary Figure 3: Inhibiton of ADAM10 and ADAM17 compromises 
sphere forming capacity of GSC. GS-5 cells were dissociated to a single cell 
suspension and 10, 100 and 1000 cells respectively were seeded in 96 well plates in 
triplicates. The cells were treated with either DMSO, GI254023X or GW280264X (3 
µM each) for 14 days. Then the number of spheres was counted in each well using a 
2 
light microscope. Results represent mean number of spheres ± SD. One 
representative out of two experiments is shown. 
